Insider Buying: Caribou Biosciences, Inc. (NASDAQ:CRBU) CEO Buys $20,400.00 in Stock

Caribou Biosciences, Inc. (NASDAQ:CRBU) CEO Rachel E. Haurwitz purchased 20,000 shares of the stock in a transaction on Friday, March 14th. The shares were acquired at an average cost of $1.02 per share, with a total value of $20,400.00. Following the transaction, the chief executive officer now directly owns 3,369,395 shares in the company, valued at $3,436,782.90. The trade was a 0.60 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

Caribou Biosciences Stock Performance

Shares of NASDAQ:CRBU opened at $0.95 on Thursday. Caribou Biosciences, Inc. has a 52-week low of $0.95 and a 52-week high of $5.77. The firm has a market capitalization of $88.44 million, a P/E ratio of -0.58 and a beta of 2.34. The stock has a 50 day moving average price of $1.32 and a 200-day moving average price of $1.75.

Caribou Biosciences (NASDAQ:CRBU) last announced its earnings results on Monday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.01. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The firm had revenue of $2.08 million during the quarter, compared to analyst estimates of $2.11 million. On average, equities analysts forecast that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CRBU has been the subject of a number of recent analyst reports. Bank of America lowered their price target on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Citigroup lowered their price target on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, November 26th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a research report on Wednesday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $10.33.

Institutional Trading of Caribou Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. PFM Health Sciences LP grew its stake in shares of Caribou Biosciences by 5.5% in the 3rd quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock worth $8,441,000 after buying an additional 223,299 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Caribou Biosciences by 475.9% in the 4th quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company’s stock worth $3,969,000 after buying an additional 2,062,563 shares during the last quarter. Schonfeld Strategic Advisors LLC grew its stake in shares of Caribou Biosciences by 28.4% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company’s stock worth $3,360,000 after buying an additional 467,738 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Caribou Biosciences by 6.5% in the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock worth $3,980,000 after buying an additional 124,782 shares during the last quarter. Finally, FMR LLC grew its stake in shares of Caribou Biosciences by 7.4% in the 3rd quarter. FMR LLC now owns 1,581,493 shares of the company’s stock worth $3,100,000 after buying an additional 109,606 shares during the last quarter. Hedge funds and other institutional investors own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.